Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Cenicriviroc & Non-alcoholic Steatohepatitis (NASH)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Cenicriviroc has shown anti-fibrotic activity in murine models of Non-Alcoholic Steatohepatitis (NASH / MASH) and has been evaluated in clinical trials on patients with Non-alcoholic Steatohepatitis (NASH)
Chen et al. 2024 Endocrinology bqae069

Cenicriviroc prevented and reversed hepatic steatosis, insulin resistance, inflammation, and fibrogenesis in the livers of Non-Alcoholic Steatohepatitis (NASH / MASH) mice via M2 [macrophage polarization](brain://sVZvN__SKkKK_FVBzg035g/M…

References (Sources)

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Friedman et al. 2018 Hepatology 67(5): 1754-1767
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Tacke 2018 Exp Opin Invest Drugs 27: 301-311
Cenicriviroc suppresses and reverses steatohepatitis by regulating macrophage infiltration and M2 polarization in mice
Chen et al. 2024 Endocrinology bqae069

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Cenicriviroc & Non-alcoholic Steatohepatitis (NASH)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat